Centre for Probe Development and Commercialization (CPDC) and adMare BioInnovations (adMare) have created a new initiative to advance radiopharmaceuticals in Canada.
The CDPC-adMare Radiopharmaceutical Initiative (CARI) combines the resources of the two companies in order to commercialize promising radiopharmaceutical innovations.
CARI's goal is to discover radiopharmaceutical opportunities from academia and early-stage companies in order to establish related drug development programs. CDPC and adMare also hope to generate a proof of principle and other data to support commercialization efforts.
